Cardiovascular implantable electronic device endocarditis treated with daptomycin with or without transvenous removal  by Tascini, Carlo et al.
Cardiovascular implantable electronic device endocarditis
treated with daptomycin with or without
transvenous removalCarlo Tascini, MDa, Maria Grazia Bongiorni, MDb, Andrea Di Cori, MDb,
Antonello Di Paolo, MDc, Marina Polidori, MDa, Enrico Tagliaferri, MDa,*,
Serena Fondelli, MDa, Ezio Soldati, MDb, Ilaria Ciullo, BSa, Alessandro Leonildi, BSa,
Romano Danesi, PhDc, Giovanni Coluccia, MDb, Francesco Menichetti, MDa
aUnita` Operativa Malattie Infettive, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
bUnita` Operativa Cardiologia II, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
cDivisione di Farmacologia e Chemioterapia, Universita` di Pisa, Pisa, Italya r t i c l e i n f o
Article history:
Received 20 November 2011
Revised 4 February 2012
Accepted 6 February 2012
Online 20 March 12Keywords:
Daptomycin
Cardiovascular implantable
electronic device
Endocarditis
Transvenous removalConflict of interest: In the past 2 years, C.T.
* Corresponding author: EnricoTagliaferri,MD
E-mail address: tagliaferrienrico@alice.it
0147-9563  2012 Elsevier Inc.
doi:10.1016/j.hrtlng.2012.02.002
Open access under ta b s t r a c t
Background and Methods: Nine patients with cardiovascular implantable elec-
tronic device (CIED) endocarditiswere treatedwith daptomycin after the failure of
previous treatment. The blood and CIED lead cultures of 1 patient were negative.
In the other 8 patients, we observed 6 monomicrobic infections and 2 poly-
microbic infections. Overall, 10 strains were isolated in these patients:
4methicillin-sensitive Staphylococcus aureus, 2methicillin-sensitive Staphylococcus
epidermidis, 1 methicillin-resistant Staphylococcus aureus, 1 methicillin-resistant
Staphylococcus epidermidis, 1 methicillin-sensitive Staphylococcus hominis, and 1
Propionibacterium acnes. The CIED was removed transvenously in 7 patients. Two
patients were too sick for the removal of their CIED, and were cured with 6mg/kg
of daptomycin for 60 and 110 days, respectively, without adverse events.
Results: One patient died 4 days after the removal of his CIED because of a compli-
cated abdominal aortic aneurysm. The other 8 patients were cured, with a mean
follow-up of 17  8 months. The removed leads were negative, after daptomycin
therapy, in 4 cases out of 7. Themean ratio betweenpeakdaptomycin concentration
andminimal inhibitory concentration (MIC) of the causative strainswas 38.3 18.5.
For patients whose data were available, the ratio between peak daptomycin
concentration andminimal bactericidal concentration (MBC) was 13.2 3.2.
Conclusion: Daptomycin monotherapy may be a useful therapeutic tool in
difficult-to-treat CIED endocarditis, resulting in a high rate of cures and steril-
ized leads removed. The ratio between peak daptomycin concentration and MIC
or MBC may be useful as predictive tool for treatment success.has been paid for lectures on behalf of Pfizer, Merck Sharp and Dhome, and Novartis.
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infection is a growing problem, because more devices
are being implanted. In previous years, pacemaker (PM)
infection ranged between 0.13%1 and 19.9%.2 Pace-
maker endocarditis accounts approximately for 10% of
PM infections.3 In the United States, among Medicare
beneficiaries, the rate of infection increased by 124%
from 1990 to 1999.4 The incidence of CIED infections in
a large survey was 1.9/1000 device/years, with an
incidence of pocket infections alone of 1.37/1000
device/years and an incidence of systemic infections
and endocarditis of 1.17/1000 device/years.5
Staphylococci, and especially coagulase-negative
Staphylococci (CoNS), account for 60% to 80% of cases
in most reported series. Methicillin resistance (MR)
among Staphylococci varies among studies, but a low
frequency of methicillin-resistant CoNS was reported
among individuals with no healthcare contact,6
whereas a high rate of MR in CoNS is associated with
a healthcare environment source.7
Coagulase-negative Staphylococci are able to produce
an extracellular slime and to constitute a biofilm that
functions as a virulence factor. In this way, they adhere
to plastic and metallic devices such as CIEDs. Microbes
in biofilm are more resistant to antibiotics and host
defenses.
Daptomycin is a bactericidal cyclic molecule of
a class of antibiotics, the lipopeptides. No other prod-
ucts from this class are in clinical use. It is active against
Gram-positive microorganisms. It was approved for
skin and soft-tissue infections, and subsequently for
right-side endocarditis and bacteremia attributable to
Staphylococcus aureus, in response to a randomized
study on bacteremia and endocarditis comparing dap-
tomycin with standard therapy.8,9 In an in vitro study
comparing the ability of various antibiotics to eradicate
Staphylococci embedded in biofilm, daptomycin proved
to be most effective after short-term exposure.10 In
earlier studies itwas showntopenetratehomogenously
into the core of cardiac vegetations of endocarditis.11
Nuovo Santa Chiara Hospital in Pisa is the Italian
reference center for the transvenous removal of
CIEDs.12,13 Because daptomycin is approved for right-
side endocarditis, and is bactericidal on plankton
bacteria and on slime-producing Staphylococci, we
decided to use daptomycin in CIED-associated endo-
carditis that failed to respond to other antibiotics.Materials and MethodsThemedical records of patients admitted to PisaHospital
from September 2007 to February 2010 for PM orintracardiac device (ICD) endocarditis were reviewed.
Patients with CIED-associated endocarditis who had
been treated with daptomycin after the failure of
previous treatments were included in the study. Age,
gender, predisposing conditions, and previous antibiotic
therapieswere reviewed. For a diagnosis of endocarditis,
the modified Duke criteria were used.14 Results of blood
cultures, CIED pocket material cultures, and cultures of
leadtipswere recorded.Dose,duration,andblood levelof
daptomycin were recorded. Patients were considered
cured if no signs of infection were evident at least 6
months after the end of daptomycin or other antibiotic
therapy initiated as domiciliary therapy after treatment
with daptomycin.
All removal procedures were performed using
a mechanical dilatation method and with aseptic tech-
nique. Surgical facilities were present in the electro-
physiology laboratory, and cardiosurgical standby was
available in the Cardiothoracic Department, Azienda
Ospedaliera Universitaria Pisana. Extraction procedures
were performed as previously described.12,13 A new
transjugular approach was used when appropriate.
At our center, we developed an approach through
the internal jugular vein (a transjugular approach) to
remove free-floating leads and difficult exposed leads.
Free-floating leads were grasped and then exposed
through the jugular vein. After the proximal ends
were exposed, they were submitted to a standard
procedure for exposed leads. In the presence of diffi-
cult exposed leads, the approach required slipping the
lead to make it free-floating. The lead could then be
exposed through the jugular vein and subsequently
dilated.
The microbiology of an infection was documented
by culturing on solid media (chocolate agar, McConkey
agar, mannitol salt agar, or Sabouroud agar), the
removed catheter leads (the proximal and distal parts),
or infected material from the pocket. The tip or other
parts of the leads were rolled onto the solid media. The
material drawn from the pocket was spread directly on
the culture plate; the leads were cultured on the plate
by direct rolling. Two sets of aerobic and anaerobic
blood cultures were taken after removal and in case of
fever in all patients. The blood cultures system we
used was BACTEC 9240 (Becton-Dickinson, Milan,
Italy). For the identification of organisms, an auto-
mated system (API, Bio-Merieux, Mercy L’Etoile,
France) was used.
Ratios of minimal inhibitory concentration (MIC)/
minimal bactericidal concentration (MBC) of the caus-
ative strains were performed using 2-fold dilution on
cation-adjusted Mueller-Hinton broth (Oxoid, Ltd.,
Basingstoke,Hampshire,UK)andan inoculumof5105
colony-forming units (CFUs)/mL. The plates were
Table 1 e Characteristics of patients with CIED endocarditis treated with daptomycin
Patient
no.
Age/
gender
Underlying
condition
CIED
(years)
Valve Organism
(blood or
pocket)
Previous
therapy
(days)
1 76/M IHD, AMI, stent,
diabetes, AVB, DFI
PM (6) Tricuspid MSSA (B) CRO þ G (21)
2 78/M IHD, AMI, mechanical
aortic valve, aortic
valvulated tube, AF
PM (8) Aortic, mitral,
tricuspid
MSSA (B) OXA þ R (10)
3 74/M IHD, AMI, AVB ICD (2) Tricuspid þ
P infection
MRSE, (P) MSSE (P) CLA þ R (15)
4 77/M AMI, DCM, tachycardia ICD (4) Tricuspid Unknown CC þ R (15)
5 53/M DCM, IHD ICD (2) Tricuspid Staphylococcus
hominis MS (B)
AMC þ SXT (20)
6 88/M SND PM (1) Tricuspid þ
P infection
MSSA (B, P) AMC þ R (15)
7 49/M DCM ICD (2) Tricuspid þ PE MSSA (B) VAN þ G (12)
OXA þ G (15)
8 75/M AVB PM
(1 month)
Tricuspid þ PE MRSA (B) TEC þ R (13),
LZD þ MER (5)
9 63/M AVB, aortic stenosis,
biologic aortic valve
prosthesis, aortic
valvulated tube,
permanent bladder
catheter
PM (3) Tricuspid, aortic
prosthetic
MSSE (B) CIP þ R (40)
TEC þ MER (5)
AF, atrial fibrillation;AMC, amoxicillin/clavulanate;AMI, acutemyocardial infarction;AVB, atrioventricular block; B, blood; CC,
clindamycin; CIED, cardiovascular implantable electronic device; CIP, ciprofloxacin; CLA, clarithromycin; CRO, ceftriaxone;
DCM, dilated cardiomyopathy; DFI, diabetic foot infection; DO, doxycycline; G, gentamicin; ICD, intracardiac device; IHD,
ischemic heart disease; LZD, linezolid;MER,meropenem;MOX,moxifloxacin;MRSA,methicillin-resistant Staphylococcus aureus;
MRSE, methicillin-resistant Staphylococcus epidermidis;MSSA, methicillin-sensitive Staphylococcus aureus;MSSE, methicillin-
sensitive Staphylococcus epidermidis; OXA, oxacillin; P, pocket; PE, pulmonary embolism; PIP/TZB, piperacillin/tazobactam; PM,
pacemaker; R, rifampicin; SND, sinus node dysfunction; SXT, cotrimoxazole; TEC, teicoplanin; VAN, vancomycin.
h e a r t & l ung 4 1 ( 2 0 1 2 ) e 2 4ee 3 0e26incubated for 20 to 24 hours, and the MICs were read.
Thereafter, clear wells were subcultivated and CFUs
were counted. MBCs were defined as the lowest antibi-
otic concentration that decreased the final inoculum by
99.9%. For daptomycin, a Mueller-Hinton broth with
50 mg/mL calciumwasused. The removal of the infected
CIEDwasperformedafter at least 10daysofdaptomycin
therapy.
Daptomycin concentrations were measured using
a high-performance chromatographic method with
ultraviolet detection. Briefly, 100 mL of plasma were
extracted with 200 mL of methanol, and clear superna-
tants were analyzed in a Waters Breeze apparatus
(Waters, Milford, CT) equipped with a Waters 2476
dual-wavelength ultraviolet detector set at 214 nm. The
elution of standardswas obtained isocratically through
a BDS C8 Hypersil chromatographic column (250  4.6
mm, 5 mm; Phenomenex, Torrance, CA), using an
acetonitrile/phosphate buffer mobile phase.15 Creatin
phosphokinase was monitored every 5 days. During
each visit, patients were checked for muscle pain or
toxicity.Ethics
Ethics Committee of the Azienda Ospedaliera Uni-
versitaria Pisana approval for this research study
(protocol number 55945) was obtained on September
24, 2009.ResultsOverall, 290 patients with CIED infection were treated
at our center during the 3-year study period. Nine
patients with CIED endocarditis were treated with
daptomycin after the failure of previous treatments,
and were included in this study. Table 1 summarizes
the characteristics of patients and treatment regimens.
All patients were male, and their mean age was 70  12
years. One patient’s blood and PM lead cultures
tested negative (patient 4). In the other 8 patients,
we observed 6 monomicrobic infections and 2 poly-
microbic infections. Overall, 10 strains were isolated in
Dose of
daptomycin
(mg/kg)
Associated
antibiotics
Duration
(days)
CIED
culture
Treatment after
extraction or end of
daptomycin
treatment(months)
CIED
implantation
(days from
explant)
Outcome
(months of
follow-up)
6 No 60 No extraction AMC (1) No Cure (6)
6 No 110 No extraction AMC (1) No Cure (12)
6 PIP/TZB (10) 30 (25 before) Yes, MRSE, MSSE Yes (4) Death on day 5
from rupture
of abdominal
aneurysm
6 PIP/TZB (10) 20 (5 before) Yes, negative Yes (4) Cure (18)
6 No 90 (90 before) Yes, negative DO þ R (3) Yes (165) Cure (6)
6 No 30 (20 before) Yes, negative AMC þ DO (1),
DO þ R (2)
Yes (2) Cure (24)
6 No 20 (20 before) Yes, negative MOX þ R (2) Yes (2) Cure (24)
6 No 26 (15 before) Yes, MRSA DO þ
R (15 days)
Yes (32) Cure (24)
8 No 55 (30 before) Yes,
Propionibacterium
acnes
No Cure (24)
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aureus (MSSA), 2 methicillin-sensitive Staphylococcus
epidermidis (MSSE), 1 methicillin-resistant Staphylo-
coccus aureus (MRSA), 1 methicillin-resistant Staphylo-
coccus epidermidis, 1 S. hominis methicillin susceptible,
and 1 Propionibacterium acnes. Five patients exhibited
a PM infection, and 4 patients exhibited an ICD infec-
tion. Infected CIEDs had been implanted a mean of 3.1
 2.5 years previously, suggesting that these were late
CIED infections. In only 1 case (patient 8) had a PM been
implanted only 1 month before the first signs of infec-
tion. All 9 patients had endocarditis, according to the
Duke criteria, involving the tricuspid valve. In 7
patients, tricuspid endocarditis was confirmed by
intracardiac echocardiography. In the other 2, CIED
right-side endocarditis was confirmed by trans-
esophageal echocardiography. In 2 patients, the left
valves were involved. In 1 patient, the aortic mechan-
ical and native mitral valves were affected (patient 2),
whereas in the other, only the mechanical aortic valve
was affected (patient 9). In patient 4, a microorganism
was not isolated, but that patient fulfilled the criteriafor the diagnosis of endocarditis: vegetation according
to transthoracic echocardiography, fever, a predispos-
ing heart condition, and a positive rheumatoid factor.
In all 9 patients, daptomycin was initiated after the
clinical or microbiological failure of previous therapy.
Daptomycin was administered at 6 mg/kg in all
patients, except for patient 9, who received 8 mg/kg.
Daptomycin was administered for a mean of 49  32
days. Daptomycin was administered before CIED
removal for 29.2  27.6 days in the 7 patients in whom
a CIED was removed transvenously. Daptomycin was
administered as monotherapy in 6 patients. In 2
patients, piperacillin/tazobactam as empiric anti-
Gram-negative therapy was combined with daptomy-
cin. In patient 6, pathogen-directed rifampin therapy
was added to daptomycin for 30 days. The extraction of
the entire device was performed in 7 out of 9 patients.
In patients 1 and 2, removal of the device was consid-
ered too risky. These 2 patients were cured with pro-
longed daptomycin therapy of an MSSA right-side
endocarditis and of right and left side (prosthetic and
native valve) endocarditis, respectively (Table 1). These
Table 2 e Pharmacokinetic characteristics of patients with CIED endocarditis treated with daptomycin
Patient
no.
Trough
concentration
(mg/L)
Peak concentration
(mg/L)
MIC
(mg/L)
MBC
(mg/L)
Peak
concentration/
MIC
Peak
concentration/
MBC
1 14.2 32.8 1 MSSA 32.8
2 5.5 19.2 1 MSSA 2 19.2 9.6
5 15.6 55.5 1 Staphylococcus hominis 55.5
6 9.1 28.1 1 MSSA 2 28.1 14.05
8 11.8 51.3 2 MRSA 4 25.6 12.3
9 8.4 35.7 1 S. epidermidis 2 35.7 17.8
0.5 Propionibacterium acnes 71.4
Mean 10.7 37.1 38.32 13.2
SD 3.7 13.8 18.5 3.1
CIED, cardiovascular implantable electronic device; MBC, minimal bactericidal concentration; MIC, minimal inhibitory
concentration; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus.
h e a r t & l ung 4 1 ( 2 0 1 2 ) e 2 4ee 3 0e282 patients received 6 mg/kg of daptomycin for 60 and
110 days, respectively, without adverse events. Both
had a blood concentration of daptomycin measured at
steady state: for patient 1, that concentration was 32.8
mg/L, and for patient 2, it was 19.8 mg/L. Because both
had an MIC of MSSA of 1 mg/L, ratios of peak concen-
tration/MIC of 32.8 and 19.8 were obtained (Table 2). In
the other 7 patients, the CIED was removed trans-
venously. In 4 cases, CIED lead tip cultures tested
negative. Of these patients, 1 had an unknown infec-
tion,whereas the other 3 had previously yielded several
blood cultures positive for MSSA (2 patients) and S.
hominis in (1 patient). In the other 3 patients, CIED lead
tip cultures tested positive, and in 2 cases, the result
was consistent with the microorganisms of previous
cultures. In patient 9, the CIED culture was positive for
P. acnes, whereas several blood cultures were previ-
ously positive for MSSE.
In 6 patients, the CIED was reimplanted. In 4
patients, it was implanted during daptomycin therapy,
in 2 patients it was implanted 2 days after removal of
the infected CIED, and in the other 2 it was implanted 4
days after removal of the infected CIED. One patient
died 4 days after removal of the CIED because of
a complicated abdominal aortic aneurysm. The other 8
patients were cured (mean follow-up, 17  8 months).
Six patients were treated with other antibiotics after
the removal of their CIED (Table 1).
Daptomycin blood levels were available in 6 patients.
The troughmean blood concentration was 9.5 4.1 mg/
L,whereas themeanpeakblood levelwas37.1 13.8mg/
L. In these 6 patients, we were able to calculate the ratio
between peak concentration and MIC of daptomycin of
the causative strain: this ratio was 38.3  18.5, ranging
from 19.2 to 71.4 (Table 2). Because we did not have the
daptomycin concentration of the patientwhohad died 4
days after the extraction, we may speculate that the
mean value of 38.3 for this ratio, as obtained in patients
whowerecured,maybe thegoal fordaptomycin therapy
in these patients. Values of the ratio between peak
concentration and MBC for the 4 available isolates are
listed in Table 2. Themean value was 13.2 3.1, rangingfrom9.6 to 17.8 (Table 2). No adverse event related to the
administration of daptomycin was evident.Discussion
The removal of all hardware is recommended for
established CIED infections, and especially endocardi-
tis.16,17 Attempts to apply antibiotic therapy alone have
beenmostly unsuccessful, at around 90% rate of failure
in published series.18-20 Percutaneous lead extraction
has become the preferred method for the removal of
CIEDs, although it is not free of complications such
as cardiac tamponade and pulmonary embolism.
However, in high-volume centers, it can be relatively
safe, with a high rate of success. Percutaneous lead
removal may pose a risk of pulmonary embolism in
cases of endocarditis with vegetation >2 cm. In these
cases, the decision relies on the patient’s characteris-
tics and the experience of the extractor. Only patient 6
manifested vegetation of >2 cm, and therefore he was
treated for several months with antibiotics and anti-
coagulant before extraction.
Patients 1 and 2 were too sick for the removal of
their CIED. Therefore, only antibiotic therapy was
performed. These 2 patients were cured with pro-
longed therapy. Because of its bactericidal activity and
ability to penetrate biofilm, daptomycin has been used
successfully to treat prosthetic valve endocarditis in
patients for whom valve removal was not a therapeutic
option.21 But in terms of CIED-associated endocarditis,
these are the first 2 cases, to the best of our knowledge,
in which daptomycin was able to cure an infection
without removal of the hardware. In fact, Cunha et al
described a case of endocarditis cured without surgery,
but only after removal of the entire PM, and the
cultures of the electric wires remained positive for
MSSA.22
The optimal timing of device replacement is
unknown, and no prospective trials have examined the
time of replacement and risk for relapse of infection.
h e a r t & l ung 4 1 ( 2 0 1 2 ) e 2 4ee 3 0 e29Sohail et al demonstrated differences in the timing
of replacement, based on blood culture results or type
of pathogen.16 Some authors suggested a 24-hour
interval for replacement,23 and only 1 medical center
proposed simultaneous contralateral replacement of
an infected CIED, based on 16 patients with endo-
carditis.24 In 7 patients, the hardware was completely
removed. Cultures of electric wires tested negative in
3 patients with previous positive blood cultures
after 90, 15, and 20 days of daptomycin therapy,
respectively (patients 5, 6, and 7; Table 1). Because of its
bactericidal activity against slime-producing bacteria,
daptomycin may be able to sterilize the CIED, permit-
ting the insertion of a new device in patients depen-
dent on their CIED in a few days under antibiotic
coverage, without relapse of infection. In our previous
experience,13 we implanted a new device at a median
time of 48 hours. In this series involving treatment
with daptomycin, we reinserted the new device more
confidently in cases of sterilized, extracted CIEDs.
Notably, these patients had negative culture results
after a daily dose of daptomycin at only 6 mg/kg. In
patient 8, the culture of the lead was still positive for
the causative MRSA strain, with an MIC of 2 that was
considered resistant and anMBC of 4mg/L, higher than
the other MBC values found in this series. In the 2005
Cubicin Outcomes Registry and Experience findings for
daptomycin therapy, responses to MRSA were poorer
than in MSSA endocarditis, although the difference
was not statistically significant (P ¼ .34),25 suggesting
that daptomycin may be less effective against MRSA
than MSSA. Most probably, we effected a cure in
patient 8 because of complete hardware removal and
prolonged antimicrobial treatment, and we speculate
that removal of the infected device is even more
mandatory in cases of MRSA infection. Further,
a higher peak concentration of the drug was detected
in this patient.
Intracardiac echocardiography is a good tool for the
diagnosis of endocarditis, and in right-side endocardi-
tis is able to measure the real dimensions of vegetation
to establish if the vegetation is >2 cm, the limit for
transvenous removal without the risk of massive
embolism.26
In patient 6, daptomycin was administered for at
least 30 days with rifampin. In an animal study,
rifampin would seem to be a better choice with respect
to gentamicin, but clinical data on combinations of
daptomycin and rifampin are lacking.
The cure of CIED-associated endocarditis using only
bactericidal antibiotic therapy without hardware
removal may prove very rare. Furthermore, the reten-
tion of a CIED may be responsible for a high associated
mortality rate,27 especially in endocarditis. Kugener
et al reported that 16 of 19 (84%) patients treated with
antibiotics alone died, compared with only 3 of 39 from
whoma device could be removed.28 Moreover, when an
entire CIED is removed, sterilizing the leads may be
very important in the prevention of relapse. When the
removal of a CIED is difficult or contraindicated (aswith patients 1 and 2 in our series), a bactericidal drug
must be used.
A tool to measure bactericidal activity may involve
the bactericidal activity of the serum. Otherwise, the
ratio between the peak concentration and MBC may
constitute a surrogate. For the 4 patients in whom this
information was available, the mean ratio was 13.2.
This ratio may be compared with the activity of that
serum diluted up to 13 times that remains bactericidal.
Eggiman and Waldwogel suggested that in cases of
staphylococcal CIED endocarditis without the removal
of the entire device, the serum bactericidal activity has
to be more than 1:16, ie, a value similar to that which
that we found of 13.29 In the same review, they sug-
gested more than 6 weeks of therapy, and in concor-
dance, we report a mean value of 49 days. Prospective
comparative studies need to be performed to validate
daptomycin monotherapy in CIED endocarditis.ConclusionsDaptomycin, in association with the removal of an
infected device, is effective and safe in the manage-
ment of CIED endocarditis. When an infected device
cannot be removed, a prolonged course with dapto-
mycin can be effective and safe. The ratio between the
peak concentration and MBC may constitute a surro-
gate of the bactericidal activity of the serum.References
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